Jonathan Barratt
Impact in
- Nephrology top 0.01%
- Renal Diseases and Glomerulopathies
- Chronic Kidney Disease and Diabetes
- Dialysis and Renal Disease Management
- Transplantation top 1%
- Renal Transplantation Outcomes and Treatments
Papers in
- Nephrology 319
- Renal Diseases and Glomerulopathies 286
- Chronic Kidney Disease and Diabetes 29
- Dialysis and Renal Disease Management 11
- Immunology 20
- Complement system in diseases 16
- Co-authors
- John Feehally (33 shared papers)Chee Kay Cheung (32 shared papers)Jürgen Floege (30 shared papers)Karen Molyneux (24 shared papers)Brad H. Rovin (26 shared papers)Richard A. Lafayette (51 shared papers)Vladimı́r Tesař (30 shared papers)Haresh Selvaskandan (25 shared papers)
- Journals
- Kidney International Reports (63 papers)Kidney International (62 papers)Nephrology Dialysis Transplantation (53 papers)Journal of the American Society of Nephrology (40 papers)Clinical Journal of the American Society of Nephrology (10 papers)
- Partner nations
- United KingdomUnited StatesAustralia
In The Last Decade
Jonathan Barratt
350 papers receiving 17.6k citations
Jonathan Barratt's Hit Papers
Peers
Comparison fields: 5 of 153
- Nephrology 13.7k
- Transplantation 283
- Immunology 885
- Rheumatology 539
- Hematology 395
Countries citing papers authored by Jonathan Barratt
This map shows the geographic impact of Jonathan Barratt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Barratt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Barratt more than expected).
Fields of papers citing papers by Jonathan Barratt
This network shows the impact of papers produced by Jonathan Barratt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Barratt. The network helps show where Jonathan Barratt may publish in the future.
Co-authors
The 25 scholars most cited alongside Jonathan Barratt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 394 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases Hit paper breakdown → | 2021 | 1758 |
| 2 | The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification Hit paper breakdown → | 2009 | 1023 |
| 3 | Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group Hit paper breakdown → | 2017 | 895 |
| 4 | The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility Hit paper breakdown → | 2009 | 863 |
| 5 | Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases Hit paper breakdown → | 2021 | 560 |
| 6 | Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens Hit paper breakdown → | 2014 | 520 |
| 7 | Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments Hit paper breakdown → | 2014 | 400 |
| 8 | 2005 | 332 | |
| 9 | Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial Hit paper breakdown → | 2017 | 311 |
| 10 | 2001 | 275 | |
| 11 | Long-Term Outcomes in IgA Nephropathy Hit paper breakdown → | 2023 | 270 |
| 12 | 2016 | 245 | |
| 13 | 2019 | 238 | |
| 14 | 2015 | 228 | |
| 15 | 2019 | 218 | |
| 16 | 2019 | 204 | |
| 17 | Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial Hit paper breakdown → | 2023 | 199 |
| 18 | Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial Hit paper breakdown → | 2023 | 195 |
| 19 | 2007 | 180 | |
| 20 | 2020 | 179 |
About Jonathan Barratt
Jonathan Barratt is a scholar working on Nephrology, Immunology, Hematology, Statistics and Probability and Pulmonary and Respiratory Medicine, having authored 394 papers that have together received 18.2k indexed citations. Recurring topics across this work include Renal Diseases and Glomerulopathies (286 papers), Chronic Kidney Disease and Diabetes (29 papers), Complement system in diseases (16 papers), Erythropoietin and Anemia Treatment (12 papers), Dialysis and Renal Disease Management (11 papers), Vasculitis and related conditions (7 papers), Glycosylation and Glycoproteins Research (7 papers) and Statistical Methods in Clinical Trials (7 papers). The work is most often cited by research in Nephrology (13.7k citations), Transplantation (283 citations), Immunology (885 citations), Rheumatology (539 citations) and Hematology (395 citations). Jonathan Barratt has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include John Feehally, Chee Kay Cheung, Jürgen Floege, Karen Molyneux, Brad H. Rovin, Richard A. Lafayette, Vladimı́r Tesař, Haresh Selvaskandan, See Cheng Yeo and Hong Zhang. Their work appears in journals such as Kidney International Reports, Kidney International, Nephrology Dialysis Transplantation, Journal of the American Society of Nephrology and Clinical Journal of the American Society of Nephrology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.